- Home
- LIXT vs COYA Comparison
LIXT vs COYA Comparison
Compare LIXT & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIXT | COYA |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 124.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | LIXT | COYA |
|---|---|---|
| Price | $7.21 | $5.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | ★ 504.5K | 184.0K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $2.45 | $3.71 |
| 52 Week High | $8.38 | $7.75 |
Technical Indicators
Market Signals| Indicator | LIXT | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 64.05 |
| Support Level | $6.21 | $5.40 |
| Resistance Level | $7.64 | $6.22 |
| Average True Range (ATR) | 0.84 | 0.39 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 53.35 | 78.66 |
Price Performance
Historical ComparisonAbout LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.